Streetbeat News

Price Targets

SGTX

Morgan Stanley analyst Matthew Harrison maintains an Equal-Weight rating on Sigilon Therapeutics (NASDAQ:SGTX) and raises the price target from $7 to $21.

Portfolio Pulse from Benzinga Newsdesk

July 03, 2023 | 12:33 pm

NKE

Morgan Stanley analyst Alex Kurtz has maintained an Overweight rating on Nike (NYSE:NKE) but lowered the price target from $130 to $127.

Portfolio Pulse from Benzinga Newsdesk

July 03, 2023 | 12:31 pm

PAYX

Morgan Stanley analyst James Faucette has reiterated an Equal-Weight rating on Paychex (NASDAQ:PAYX) and maintained a $125 price target.

Portfolio Pulse from Benzinga Newsdesk

July 03, 2023 | 12:28 pm

ACMR

BTAI

CPA

CUBE

ETNB

ETON

IPG

MKC

NKE

PAYX

WFC

Several analyst forecasts were released on Monday, with price target changes for ACM Research, 89bio, The Interpublic Group of Companies, McCormick & Company, BioXcel Therapeutics, Wells Fargo & Company, Eton Pharmaceuticals, Paychex, CubeSmart, Copa Holdings, and International Flavors & Fragrances. Most of the companies saw their price targets increased, with a few exceptions.

Portfolio Pulse from Lisa Levin

July 03, 2023 | 12:24 pm

IFF

Morgan Stanley analyst Betsy Graseck has maintained an Overweight rating on Intl Flavors & Fragrances (IFF) but lowered the price target from $122 to $112.

Portfolio Pulse from Benzinga Newsdesk

July 03, 2023 | 12:21 pm

ACCD

Morgan Stanley analyst Ricky Goldwasser has reiterated an Equal-Weight rating on Accolade (NASDAQ:ACCD) and maintained a $14 price target.

Portfolio Pulse from Benzinga Newsdesk

July 03, 2023 | 12:11 pm

ETNB

In the last quarter, 6 analysts have provided ratings for 89bio (NASDAQ:ETNB), with 2 being bullish and 4 somewhat bullish. The company has an average 12-month price target of $37.5, with a high of $49.00 and a low of $30.00. The average price target has increased by 10.29% over the past month.

Portfolio Pulse from Benzinga Insights

July 03, 2023 | 12:04 pm

RPHM

B of A Securities analyst Jason Zemansky has initiated coverage on Reneo Pharmaceuticals (NASDAQ:RPHM) with a Buy rating and a price target of $23.

Portfolio Pulse from richadhand@benzinga.com

July 03, 2023 | 11:55 am

AGEN

EF Hutton analyst Tony Butler has reiterated a 'Buy' rating on Agenus (NASDAQ:AGEN) and maintained a price target of $8.3.

Portfolio Pulse from richadhand@benzinga.com

July 03, 2023 | 11:18 am

CPA

Raymond James analyst Savanthi Syth has maintained a Strong Buy rating on Copa Holdings (NYSE:CPA) and raised the price target from $138 to $155.

Portfolio Pulse from richadhand@benzinga.com

July 03, 2023 | 11:16 am